Status:
NOT_YET_RECRUITING
Efficacy of Methylene Blue Plus Ropivacaine for Post-Hemorrhoidectomy Pain.
Lead Sponsor:
The Affiliated Hospital of Putian University
Conditions:
Mixed Hemorrhoids
Milligan-Morgan Hemorrhoidectomy
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Revised Translation (Academic English): As one of the most prevalent anorectal disorders, mixed hemorrhoids continue to rely on the Milligan-Morgan hemorrhoidectomy as the gold-standard surgical appr...
Eligibility Criteria
Inclusion
- Aged between 18 and 75 years.
- Diagnosed with Grade III-IV hemorrhoids according to the Goligher classification.
- Scheduled to undergo standard Milligan-Morgan hemorrhoidectomy.
- Procedure performed under spinal anesthesia alone.
Exclusion
- Pregnancy or lactation.
- Current immunotherapy or coagulopathies.
- Contraindications to any protocol-specified agents (e.g., history of severe allergic reactions to methylene blue or ropivacaine).
- Concurrent anorectal pathologies (e.g., perianal abscess, anal fistula, fecal incontinence).
- Comorbid systemic conditions (e.g., cardiac/hepatic/renal insufficiency, diabetes mellitus, coagulopathy, peptic ulcer disease).
- Incomplete perioperative documentation.
- Inability to comply with follow-up protocols.
Key Trial Info
Start Date :
August 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
177 Patients enrolled
Trial Details
Trial ID
NCT07164807
Start Date
August 30 2025
End Date
December 1 2026
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Affiliated Hospital of Putian University
Putian, China